NCT06794255: VitC-Aging

Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults

Recruiting now NA Last updated 27 June 2025

What this trial tests

NA trial testing Vitamin C in Ageing in 400 participants. Currently enrolling.

Timeline

2 April 2025

Primary endpoint
30 January 2026

30 January 2027

Quick facts

Lead sponsor	Peking University Third Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	400
Start date	2 April 2025
Primary completion	30 January 2026
Estimated completion	30 January 2027
Sites	3 locations across China

Drugs / interventions tested

• Vitamin C — full drug profile →
• Placebo

Conditions studied

• Ageing — all drugs for Ageing →

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 70, any sex, with Ageing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows:

* Can oral vitamin C effectively improve the aging-related indicators?
* What is the safety of participants when taking vitamin C supplements?

Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to:

* Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months;
* Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up;
* Honestly inform the medication situation during each follow-up;
* Report any discomfort or adverse reactions that occur during the treatment process to the researchers;
* Fill in a questionnaire about their own health status during each follow-up;
* After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Molecular time machines unleashed: small-molecule-driven reprogramming to reverse the senescence.
   Tang C, Zhang Z, Yang C, Li L, et al · · 2026 · PMID 41528804 · DOI 10.1093/stcltm/szaf069